For patients with diabetes, SGLT2 inhibitors are recommended from stage B, but thiazolidinediones and DPP4i saxagliptin, should be avoided due to the increased risk of HF admission linked to their use [117, 144]. Here, SLC5A2 is linked to diabetes mellitus.